Separate ANOVAs in the patients and control subjects showed that the effects of MAPT haplotype were below the threshold for significance in the 2 groups (controls F[1,38] = 3.23, p = 0.080; PD patients F[1,35] = 1.85, p = 0.183). This evidence concerns the gene MAPT and Parkinson disease.